aminosalicylate


Also found in: Dictionary.
Related to aminosalicylate: Pentasa

aminosalicylate

 [ah-me″no-sah-lis´ĭ-lāt]
any salt of p-aminosalicylic acid; they are antibacterials effective against mycobacteria and the sodium salt is used orally as a tuberculostatic.

aminosalicylate

/ami·no·sa·lic·y·late/ (-sah-lis´ĭ-lāt) any salt of p- aminosalicylic acid; they are antibacterials effective against mycobacteria and the sodium salt is used as a tuberculostatic.
References in periodicals archive ?
Medical therapy for inflammatory bowel disease was grouped by class, including aminosalicylates, steroids, immune modulators (azathioprine, 6-mercaptopurine, methotrexate, and cyclosporine), and anti-TNF inhibitors (infliximab and adalimumab).
Effects of aminosalicylates on thiopurine Smethyltransferase activity: an ex vivo study in patients with inflammatory bowel disease.
For an individual with a heterozygous genotype to present a low-activity phenotype, the aminosalicylate treatment would have to cause a reduction in TPMT activity up to 15-fold.
Sulfasalazine is a compound that consists of an aminosalicylate group (5-ASA) hooked to a sulfur component.
APRISO[TM] is a locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis in patients 18 years and older.
This randomised, double-blind, placebo-controlled Phase IIIb clinical study will evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.
The study is expected to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients who have mild or moderate active ulcerative colitis who are not controlled on background 5-ASA therapy.
Because to the best of our knowledge there has been no systematic investigation on whether the sample pretreatment procedure influences the determination of the TPMT activity in patients receiving aminosalicylate therapy, we performed in vitro experiments to clarify this uncertainty.
UCERIS Phase IIIb clinical study: Patient enrollment continues in a clinical study designed to evaluate whether there is an incremental benefit in remission rate when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild to moderate active ulcerative colitis not adequately controlled on 5-ASA therapy.
The study enrolled 299 patients whose Crohn's disease had not responded to treatment with an aminosalicylate, steroids, or immunomodulator drugs.